ABSTRACT: Introduction: Recessive mutations in the anoctamin-5-encoding gene (ANO5) cause muscular dystrophy of various phenotypes. Intramuscular interstitial amyloid deposits were detected in a few patients with anoctaminopathy-5, some with cardiac involvement. The frequency of amyloid deposition in anoctaminopathy-5 and its impact on phenotype are unknown. Methods: We retrospectively identified patients with genetically proven anoctaminopathy-5 who had undergone muscle biopsy and reviewed their clinical and laboratory data. Results: Eight of 15 patients with anoctaminopathy-5 had intramuscular interstitial amyloid deposits. The median age at onset of weakness was 40 and 45 years in the amyloidosis and nonamyloidosis groups, respectively. Mutations occurred throughout the entire gene in the amyloidosis group. Atrial arrhythmia was noted in 4 patients with amyloidosis and in 4 patients without amyloidosis. The latter group also had premature ventricular contractions. One nonamyloidosis patient had septal hypokinesia. Discussion: Intramuscular amyloidosis occurred in 53% of patients with anoctaminopathy-5 who underwent muscle biopsy and had no impact on the phenotype. Anoctamin-5 (ANO5) is a calcium-activated chloride channel expressed in human bone and in cardiac and skeletal muscle 1 and plays an important role in membrane-repair machinery.
2 Dominant ANO5 mutations cause gnathodiaphyseal dysplasia. 3 Recessive ANO5 mutations cause various skeletal muscle phenotypes, including limb-girdle muscular dystrophy (LGMD) type 2L, distal myopathy with early calf muscle involvement (Miyoshi myopathy), asymptomatic hyperCKemia, and myalgia with or without rhabdomyolysis. 4 The estimated prevalence of skeletal muscle anoctaminopathy-5 is 0.27 per 100,000 in northern England. 5 We first reported skeletal muscle interstitial amyloidosis in 3 patients with anoctaminopathy-5, 2 of whom had atrial arrhythmia.
6,7 van der Kooi et al. 8 later reported a patient with anoctaminopathy-5 with skeletal muscle interstitial amyloidosis and hypertrophic cardiomyopathy. Subsequently, 2 patients with anoctaminopathy-5 with dilated cardiomyopathy and a cohort of patients with anoctaminopathy-5 with premature ventricular contractions (PVC) were described, but no information was provided regarding the histopathological studies that are usually performed to search for intramuscular interstitial amyloid deposits in the skeletal muscle of these patients. 9, 10 Recently, we showed that anoctaminopathy-5 is the most common cause of isolated amyloid myopathy, but the frequency of skeletal muscle interstitial amyloidosis, its impact on the phenotype, and the amyloidogenic protein are still unknown. 11 In this study, we sought to identify the frequency of skeletal muscle interstitial amyloidosis in recessive anoctaminopathy-5 and to compare the clinical and laboratory data between anoctaminopathy-5 patients with skeletal muscle interstitial amyloidosis and those without skeletal muscle interstitial amyloidosis, especially with regard to cardiac involvement.
PATIENTS AND METHODS
After obtaining approval from the Mayo Clinic institutional review board, we searched the Mayo Clinic database to identify patients with genetically proven, recessive anoctaminopathy-5 who had been seen between January 2010 and October 2017. We excluded patients with genetically proven anoctaminopathy-5 who had not undergone muscle biopsy. Clinical, laboratory, histopathological, and molecular data were reviewed. Severity of Additional supporting information may be found in the online version of this article.
the weakness was based on the Medical Research Council (MRC) grade of the weakest muscle group: none (grade 5/5), mild (grades 4 and 4+/5), moderate (grades 3 and 4−/5), and severe (grades < 3/5). Biopsies were taken from different muscles at the treating physicians' discretion. Generally, biopsies were performed in muscle with MRC grade 4 by manual muscle testing. In patients without objective weakness, biopsies were obtained from the muscle with the most prominent myopathic changes (short duration, low amplitude motor unit potentials, and early recruitment) according to needle electromyography (EMG). Congo red staining, the most sensitive method to detect amyloid in frozen muscle tissue, 12 was routinely performed on all muscle biopsies in our diagnostic muscle laboratory, and the slides were reviewed under rhodamine optics. Systemic amyloidosis was excluded by using the criteria published by the authors. 11 The Fisher exact test was applied to compare the discrete data between anoctaminopathy-5 patients with amyloidosis and those without amyloidosis, and the Mann-Whitney U-test was used to compare continuous variables between these 2 groups.
RESULTS
Phenotype. We identified 16 patients (5 women and 11 men) with recessive anoctaminopathy-5 (LGMD = 13, no weakness = 2, generalized limb weakness = 1). We excluded 1 ANO5-LGMD patient (homozygous c.191dupA mutation) with normal cardiac evaluation who had not undergone muscle biopsy. Among the 15 included patients, 8 (1 woman and 7 men) had skeletal muscle interstitial amyloidosis (Supp. Info. Fig. 1 ) without evidence of systemic amyloidosis. Some of the clinical information and molecular data of the included 8 anoctaminopathy-5 patients with intramuscular interstitial amyloidosis and 4 anoctaminopathy-5 patients without intramuscular interstitial amyloidosis have been previously reported. 7, 11 Table 1 displays a comparison of clinical and EMG findings between anoctaminopathy-5 patients with muscular interstitial amyloidosis and those without muscular interstitial amyloidosis (all with P-value > 0.05). Anoctaminopathy-5 patients with amyloidosis had a slightly earlier weakness onset compared with those without amyloidosis, but there were no significant differences between the 2 groups in pattern or severity of weakness, incidence of rhabdomyolysis, degree of creatine kinase (CK) elevation or EMG findings. Muscle biopsy revealed a few necrotic fibers in 8 anoctaminopathy-5 patients with muscular interstitial amyloidosis and 3 anoctaminopathy-5 patients without muscular interstitial amyloidosis (P < 0.05). There was no other significant histopathological difference between the 2 groups. Table 2 summarizes cardiopulmonary findings in anoctaminopathy-5 patients with muscle interstitial amyloidosis and those without skeletal muscle interstitial amyloidosis.
Genotype. Figure 1 summarizes the ANO5 mutations identified in our cohort and in the additional 4 anoctaminopathy-5 patients with skeletal muscle amyloidosis reported in the literature. 8, [13] [14] [15] Mutations associated with amyloid deposits in muscle were scattered throughout the entire gene. The common c.191dupA mutation was identified in 5 patients with amyloidosis (homozygous = 1, compound heterozygous = 4) and in 4 patients without amyloidosis (compound heterozygous = 4).
DISCUSSION
Skeletal muscle interstitial amyloidosis occurred in 8 of 15 (53%) patients with recessive anoctaminopathy-5 in our cohort. It is possible that the frequency of interstitial amyloidosis was underestimated. Just as in other muscle pathology, amyloid could present in a patchy pattern and could be missed because of sampling issues. There were no significant differences in age at onset, pattern or severity of weakness, presence of rhabdomyolysis, degree of CK elevation, or electrophysiological findings between anotcaminopathy-5 patients with muscle interstitial amyloidosis and those without muscle interstitial amyloidosis. We previously reported calf atrophy as a feature to differentiate isolated amyloid myopathy (often associated with ANO5 or dysferlin gene mutations) from systemic amyloidosis-associated myopathy. 11 Although this is still true, calf atrophy occurred in anoctaminopathy-5 patients with and without amyloidosis, representing a clinical feature of anoctaminopathy-5 (as previously described) independent from the presence of amyloid. 5 The sensorimotor axonal peripheral neuropathy detected in a single patient without muscular amyloid deposits was thought to be an incidental finding, likely related to heavy alcohol consumption. Necrotic fibers occurred more frequently in the muscle biopsies of patients with amyloidosis. However, it remains unknown whether interstitial amyloidosis plays a role in muscle injury and if so, how.
Cardiac arrhythmias and subtle echocardiographic abnormalities (Table 2) were observed in both the amyloidosis and nonamyloidosis groups. There was no correlation between cardiac phenotype and mutation type/location in our small cohort of patients with anoctaminopathy-5. Ejection fraction was preserved, and no fatal cardiac arrhythmia was recorded in any of our patients. In contrast to a study by Witting et al. 10 that showed an increased frequency of PVCs in patients with anoctaminopathy-5, atrial arrhythmia was more common than ventricular arrhythmia in our cohort. Premature ventricular complexes were observed only in the nonamyloidosis group. One patient in the nonamyloidosis group had septal hypokinesia. No patient had cardiomyopathy. A 35-year-old patient of ours with homozygous ANO5 c.191dupA and skeletal muscle interstitial amyloidosis 11 had sinus bradycardia and borderline global averaged left ventricular longitudinal peak systolic strain revealed by echocardiogram without overt cardiomyopathy. van der Kooi and colleagues 8 reported an older patient with the same genotype and skeletal muscle interstitial amyloidosis who had hypertrophic cardiomyopathy. Therefore, no conclusion can be made at this time regarding risk of cardiac complications in relation to the presence of amyloid in skeletal muscle.
Regarding respiratory muscle involvement, there was no difference between patients with and without amyloidosis. Three patients with amyloidosis and 2 without amyloidosis had abnormal pulmonary function test results, but none required ventilatory support. Respiratory insufficiency in anoctaminopathy-5 is rare. Bohlega et al. 15 reported 2 patients with transient dyspnea but provided no details on the pulmonary evaluation, while Savarese et al. 16 reported a 71-year-old patient with low forced vital capacity (FVC) requiring noninvasive ventilatory support.
ANO5 mutations associated with amyloidosis occur throughout the gene. There is no apparent genotypephenotype correlation with regard to the presence of interstitial amyloidosis in muscle. Homozygous c.191dupA mutations were reported by us and others to be associated with intramuscular amyloidosis. 8, 11 The c.191dupA is the most common ANO5 mutation and is a founder mutation in Northern European patients, 5 and approximately 25%-75% of patients with anoctaminopathy-5 are homozygous for this mutation. 5, 8, 17 It would be of interest to determine whether the prevalence of skeletal muscle interstitial amyloidosis in Northern European patients with anoctaminopathy-5 is higher than that observed in our cohort.
Our study provides evidence that interstitial amyloidosis in skeletal muscle is common in anoctaminopathy-5, but its presence does not seem to have a significant impact on clinical, electrophysiological, or cardiopulmonary features. ANO5 mutations associated with amyloidosis occurred throughout the whole gene. Atrial arrhythmia was more common than ventricular arrhythmia. The amyloidogenic protein and the mechanism leading to amyloidogenesis in anoctaminopathy-5 remain to be elucidated. This study is limited by the small number of patients and its retrospective nature, and larger, prospective, longitudinal studies are required for more accurate affirmation of our findings.
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